Anticancer agent

US9156827B2 · kind B2 · utility

Assignees

• THE UNIVERSITY OF TOKYO · JP
• RIKEN · JP

Inventors

• Tetsuo Nagano · Tokyo, JP
• Takayoshi Okabe · Tokyo, JP
• Hirotatsu Kojima · Tokyo, JP
• Nae Saito · Tokyo, JP
• Hirofumi Nakano · Machida, JP
• Masanao Abe · Tokyo, JP
• Akiko Tanaka · Clearwater, US
• Teruki Honma · Tsukuba, JP
• Shigeyuki Yokoyama · Yokohama, JP
• Keiko Tsuganezawa · Yokohama, JP
• Hitomi Yuki · Yokohama, JP

Key dates

• Filing date: Apr 28, 2011
• Grant date: Oct 13, 2015
• Expiry date: Jul 22, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D493/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An anticancer agent comprising a compound represented by the formula (I) [R1 represents hydrogen atom, hydroxyl group, a C1-6 alkoxy group and the like; R2 and R3 represents hydrogen atom, a halogen atom, a C1-6 alkyl group and the like; R4 represents hydrogen atom, a C1-6 alkyl group, a C1-6 alkylsulfonyl group and the like; R5 represents hydrogen atom or a substituent; represents a single bond or a double bond; R6 and R7 represents hydrogen atom, a C1-6 alkyl group and the like; R8 represents hydrogen atom, a C1-6 alkyl group and the like; A represents —O—, —S—, or —CH2—; D represents —C═ or —N═; X represents methylene group, —O—, or —CO—; Q represents —N═ or —C(R8)═; and Y represents a heterocyclic group or amino group], which shows a superior inhibitory activity against pim-1 kinase.